The shares of this company recovered over 5 percent on Tuesday from its day’s low of Rs 57.92 per share after it declared its financial results and announced a dividend of Rs 0.20 per share after a long wait of 23 years.
With a market capitalization of Rs 3,287 crores, the shares of Morepen Laboratories closed at Rs 60 per share, down by 40.5 percent from its 52-week high of Rs 100.90 per share.
Financial Highlights
Morepen Laboratories reported a revenue growth of 7.22 percent to Rs 1,812 crores in FY25, up from Rs 1,690 crores in FY24. On a year-on-year (YoY) basis, revenue surged by 10.16 percent to Rs 466 crores in Q4 FY25 from Rs 423 crores in Q4 FY24. On a quarter-on-quarter (QoQ) basis, revenue rose by 2.87 percent from Rs 453 crores in Q3 FY25.
In terms of profitability, the company recorded its highest-ever net profit of Rs 118 crores in FY25, up by 21.65 percent from Rs 97 crores in FY24. However, on a YoY basis, net profit declined by 31.03 percent to Rs 20 crores in Q4 FY25 from Rs 29 crores in Q4 FY24. Additionally, it declined by 25.93 percent from Rs 27 crores in Q3 FY25, reflecting some pressure on the bottom line in the last few quarters.
It announced a dividend, after a long 23 years of wait, of Rs 0.20 per equity share on a face value of Rs 2, subject to approval of the members of the Company at the ensuing Annual General Meeting.
Also read: Zee Entertainment’s ₹134 Cr Clash With Aditya Birla Finance Ends in Victory: What It Means for Investors
Segment Highlights
Its pharma business (total pharma) reported an annualised growth of 5.8 percent to Rs 1,334 crores in FY25 from Rs 1,261 crores in FY24. Additionally, on a year-on-year basis, it reported a growth of 8.5 percent to Rs 368 crores in Q4 FY25 from Rs 338 crores in Q4 FY24.
Its medical devices business reported an annualised growth of 12 percent to Rs 496 crores in FY25 from Rs 443 crores in FY24. Additionally, on a year-on-year basis, it reported a growth of 15 percent to Rs 103 crores in Q4 FY25 from Rs 89 crores in Q4 FY24.
About the company
Morepen Laboratories manufactures and markets pharmaceuticals such as APIs, health devices, and OTC products in India and overseas, providing aid for diseases such as allergies, diabetes, and hypertension, and diagnostic products such as thermometers and glucose meters. Dr. Morepen’s portfolio consists of products for fever, pain, acidity, and overall well-being.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
